Steady state serum concentrations of pravastatin and digoxin when given in combination.
Pravastatin is an HMG CoA reductase inhibitor used in the treatment of hypercholesterolaemia. The steady state pharmacokinetics of pravastatin (20 mg) and digoxin (0.2 mg) were evaluated in 18 healthy male subjects following the administration of each drug alone or in combination for 9 days. Serum and urine were collected for up to 48 h after the ninth dose in this open, randomized 3-way crossover study. Digoxin concentrations were measured by radioimmunoassay, and pravastatin and its metabolites. SQ 31,906 and SQ 31,945 were measured by GC-MS. Digoxin and pravastatin pharmacokinetics were unchanged following combined administration. Combination therapy with pravastatin and digoxin is unlikely to expose patients to additional risk compared with pravastatin alone.
Triscari
J
J
Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ.
Swanson
B N
BN
Willard
D A
DA
Cohen
A I
AI
Devault
A
A
Pan
H Y
HY
D000328:Adult; D000924:Anticholesteremic Agents / Q000097:blood / Q000493:pharmacokinetics*; D002316:Cardiotonic Agents / Q000097:blood / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D004077:Digoxin / Q000097:blood / Q000493:pharmacokinetics*; D004347:Drug Interactions; D006801:Humans; D008297:Male; D015394:Molecular Structure; D017035:Pravastatin / Q000097:blood / Q000493:pharmacokinetics*
D000924:Anticholesteremic Agents; D002316:Cardiotonic Agents; D004077:Digoxin; D017035:Pravastatin